nach oben

Erschienen in:

01.05.2008 | Original Article

Ly49G2 receptor blockade reduces tumor burden in a leukemia model but not in a solid tumor model

verfasst von: Melissa A. Barber, Tong Zhang, Bethany A. Gagne, Jo A. Van Ginderachter, Patrick De Baetselier, Charles L. Sentman

Erschienen in: Cancer Immunology, Immunotherapy | Ausgabe 5/2008

Einloggen, um Zugang zu erhalten

Abstract

Background

NK cell activity is regulated in part by inhibitory receptors that bind to MHC class I molecules. It is possible to enhance NK cell cytotoxicity against tumor cells by preventing the interaction of these inhibitory receptors with their MHC class I ligands.

Results

In this study, we determined that Ly49G2 is an inhibitory receptor in AKR mice for self-MHC class I, and AKR Ly49G2 has an identical sequence to BALB/c Ly49G2. Blockade of Ly49G2 receptors in vivo resulted in decreased growth of BW-Sp3 lymphoma cells when the tumor cells were given i.v. but not when the tumor cells were inoculated into the flank forming a solid tumor. However, NK cells were involved in inhibiting the growth of BW-Sp3 tumor cells in the flank.

Conclusion

These data demonstrate that the effectiveness of inhibitory receptor blockade depends upon the tissue location of the tumor cells.

Bakker AB, Phillips JH, Figdor CG, Lanier LL (1998) Killer cell inhibitory receptors for MHC class I molecules regulate lysis of melanoma cells mediated by NK cells, gamma delta T cells, and antigen-specific CTL. J Immunol 160:5239–5245PubMed

Bignon JD, Gagne K (2005) KIR matching in hematopoietic stem cell transplantation. Curr Opin Immunol 17:553–559PubMedCrossRef

Brennan J, Mahon G, Mager DL, Jefferies WA, Takei F (1996) Recognition of class I major histocompatibility complex molecules by Ly-49: specificities and domain interactions. J Exp Med 183:1553–1559PubMedCrossRef

Cerwenka A, Baron JL, Lanier LL (2001) Ectopic expression of retinoic acid early inducible-1 gene (RAE-1) permits natural killer cell-mediated rejection of a MHC class I-bearing tumor in vivo. Proc Natl Acad Sci USA 98:11521–11526PubMedCrossRef

Chang CC, Campoli M, Ferrone S (2005) Classical and nonclassical HLA class I antigen and NK Cell-activating ligand changes in malignant cells: current challenges and future directions. Adv Cancer Res 93:189–234PubMedCrossRef

Chiang EY, Henson M, Stroynowski I (2002) The nonclassical major histocompatibility complex molecule Qa-2 protects tumor cells from NK cell- and lymphokine-activated killer cell-mediated cytolysis. J Immunol 168:2200–2211PubMed

Diefenbach A, Jensen ER, Jamieson AM, Raulet DH (2001) Rae1 and H60 ligands of the NKG2D receptor stimulate tumour immunity. Nature 413:165–171PubMedCrossRef

Fahlen L, Oberg L, Brannstrom T, Khoo NK, Lendahl U,Sentman CL (2000) Ly49A expression on T cells alters T cell selection. Int Immunol 12:215–222PubMedCrossRef

Gati A, Guerra N, Giron-Michel J, Azzarone B, Angevin E, Moretta A, Chouaib S,Caignard A (2001) Tumor cells regulate the lytic activity of tumor-specific cytotoxic t lymphocytes by modulating the inhibitory natural killer receptor function. Cancer Res 61:3240–3244PubMed

10.

Geldhof AB, Moser M, Lespagnard L, Thielemans K, De Baetselier P (1998) Interleukin-12-activated natural killer cells recognize B7 costimulatory molecules on tumor cells and autologous dendritic cells. Blood 91:196–206PubMed

11.

Geldhof AB, Van Ginderachter J, Vandersteen P, Raes G, De Baetselier P (1998) Multiple effects of transfection with interleukin 2 and/or interferon gamma on the behavior of mouse T lymphoma cells. Clin Exp Metastasis 16:447–459PubMedCrossRef

12.

Geldhof AB, Van Ginderachter JA, Liu Y, Noel W, Raes G, De Baetselier P (2002) Antagonistic effect of NK cells on alternatively activated monocytes: a contribution of NK cells to CTL generation. Blood 100:4049–4058PubMedCrossRef

13.

Glas R, Sturmhofel K, Hammerling GJ, Karre K, Ljunggren HG (1992) Restoration of a tumorigenic phenotype by beta 2-microglobulin transfection to EL-4 mutant cells. J Exp Med 175:843–846PubMedCrossRef

14.

Glas R, Franksson L, Une C, Eloranta ML, Ohlen C, Orn A, Karre K (2000) Recruitment and activation of natural killer (NK) cells in vivo determined by the target cell phenotype. An adaptive component of NK cell-mediated responses. J Exp Med 191:129–138PubMedCrossRef

15.

Grundy MA, Sentman CL (2006) Immunodeficient mice have elevated numbers of NK cells in non-lymphoid tissues. Exp Cell Res 312:3920–3926PubMedCrossRef

16.

Hanke T, Takizawa H, McMahon CW, Busch DH, Pamer EG, Miller JD, Altman JD, Liu Y, Cado D, Lemonnier FA, Bjorkman PJ, Raulet DH (1999) Direct assessment of MHC class I binding by seven Ly49 inhibitory NK cell receptors. Immunity 11:67–77PubMedCrossRef

17.

Hoglund P, Glas R, Ohlen C, Ljunggren HG, Karre K (1991) Alteration of the natural killer repertoire in H-2 transgenic mice: specificity of rapid lymphoma cell clearance determined by the H-2 phenotype of the target. J Exp Med 174:327–334PubMedCrossRef

18.

Hoglund P, Ljunggren HG, Ohlen C, Ahrlund-Richter L, Scangos G, Bieberich C, Jay G, Klein G, Karre K (1988) Natural resistance against lymphoma grafts conveyed by H-2Dd transgene to C57BL mice. J Exp Med 168:1469–1474PubMedCrossRef

19.

Hsu KC, Keever-Taylor CA, Wilton A, Pinto C, Heller G, Arkun K, O’Reilly RJ, Horowitz MM, Dupont B (2005) Improved outcome in HLA-identical sibling hematopoietic stem-cell transplantation for acute myelogenous leukemia predicted by KIR and HLA genotypes. Blood 105:4878–4884PubMedCrossRef

20.

Igarashi T, Wynberg J, Srinivasan R, Becknell B, McCoy JP Jr, Takahashi Y, Suffredini DA, Linehan WM, Caligiuri MA, Childs RW (2004) Enhanced cytotoxicity of allogeneic NK cells with killer immunoglobulin-like receptor ligand incompatibility against melanoma and renal cell carcinoma cells. Blood 104:170–177PubMedCrossRef

21.

Johansson MH, Hoglund E, Nakamura MC, Ryan JC, Hoglund P (1998) Alpha1/alpha2 domains of H-2D(d), but not H-2L(d), induce “missing self” reactivity in vivo–no effect of H-2L(d) on protection against NK cells expressing the inhibitory receptor Ly49G2. Eur J Immunol 28:4198–4206PubMedCrossRef

22.

Kane KP, Lavender KJ, Ma BJ (2004) Ly-49 receptors and their functions. Crit Rev Immunol 24:321–348PubMedCrossRef

23.

Karlhofer FM, Ribaudo RK, Yokoyama WM (1992) MHC class I alloantigen specificity of Ly-49+ IL-2-activated natural killer cells. Nature 358:66–70PubMedCrossRef

24.

Karre K, Ljunggren HG, Piontek G, Kiessling (1986) Selective rejection of H-2 deficient lymphoma variants suggests alternative immune defense strategy. Nature 319:675–678PubMedCrossRef

25.

Koh CY, Ortaldo JR, Blazar BR, Bennett M, Murphy WJ (2003) NK-cell purging of leukemia: superior antitumor effects of NK cells H2 allogeneic to the tumor and augmentation with inhibitory receptor blockade. Blood 102:4067–4075PubMedCrossRef

26.

Koh CY, Raziuddin A, Welniak LA, Blazar BR, Bennett M, Murphy WJ (2002) NK inhibitory-receptor blockade for purging of leukemia: effects on hematopoietic reconstitution. Biol Blood Marrow Transplant 8:17–25PubMedCrossRef

27.

Koh CY, Blazar BR, George T, Welniak LA, Capitini CM, Raziuddin A, Murphy WJ, Bennett M (2001) Augmentation of antitumor effects by NK cell inhibitory receptor blockade in vitro and in vivo. Blood 97:3132–3137PubMedCrossRef

28.

Kumar V, McNerney ME (2005) A new self: MHC-class-I-independent natural-killer-cell self-tolerance. Nat Rev Immunol 5:363–374PubMedCrossRef

29.

Lanier LL (2005) NK cell recognition. Annu Rev Immunol 23:225–274PubMedCrossRef

30.

Makrigiannis AP, Pau AT, Saleh A, Winkler-Pickett R, Ortaldo JR, Anderson SK (2001) Class I MHC-binding characteristics of the 129/J Ly49 repertoire. J Immunol 166:5034–5043PubMed

31.

Mason LH, Ortaldo JR, Young HA, Kumar V, Bennett M, Anderson SK (1995) Cloning and functional characteristics of murine large granular lymphocyte-1: a member of the Ly-49 gene family (Ly-49G2). J Exp Med 182:293–303PubMedCrossRef

32.

Moretta L, Moretta A (2004) Killer immunoglobulin-like receptors. Curr Opin Immunol 16:626–633PubMedCrossRef

33.

Moretta L, Moretta A (2004) Unravelling natural killer cell function: triggering and inhibitory human NK receptors. Embo J 23:255–259PubMedCrossRef

34.

Ortaldo JR, Mason AT, Winkler-Pickett R, Raziuddin A, Murphy WJ, Mason LH (1999) Ly-49 receptor expression and functional analysis in multiple mouse strains. J Leukoc Biol 66:512–520PubMed

35.

Re F, Staudacher C, Zamai L, Vecchio V, Bregni M (2006) Killer cell Ig-like receptors ligand-mismatched, alloreactive natural killer cells lyse primary solid tumors. Cancer 107:640–648PubMedCrossRef

36.

Ruggeri L, Mancusi A, Capanni M, Martelli MF, Velardi A (2005) Exploitation of alloreactive NK cells in adoptive immunotherapy of cancer. Curr Opin Immunol 17:211–217PubMedCrossRef

37.

Ruggeri L, Capanni M, Urbani E, Perruccio K, Shlomchik WD, Tosti A, Posati S, Rogaia D, Frassoni F, Aversa F, Martelli MF, Velardi A (2002) Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science 295:2097–2100PubMedCrossRef

38.

Schatzle JD, Sheu S, Stepp SE, Mathew PA, Bennett M, Kumar V (1999) Characterization of inhibitory and stimulatory forms of the murine natural killer cell receptor 2B4. Proc Natl Acad Sci USA 96:3870–3875PubMedCrossRef

39.

Sentman CL, Barber MA, Barber A, Zhang T (2006) NK cell receptors as tools for cancer immunotherapy. Adv Cancer Res 95:249–292PubMedCrossRef

40.

Silver ET, Lavender KJ, Gong DE, Hazes B, Kane KP (2002) Allelic variation in the ectodomain of the inhibitory Ly-49G2 receptor alters its specificity for allogeneic and xenogeneic ligands. J Immunol 169:4752–4760PubMed

41.

Verheyden S, Bernier M, Demanet C (2004) Identification of natural killer cell receptor phenotypes associated with leukemia. Leukemia 18:2002–2007PubMedCrossRef

42.

Wetzler M, Baer MR, Stewart SJ, Donohue K, Ford L, Stewart CC, Repasky EA, Ferrone S (2001) HLA class I antigen cell surface expression is preserved on acute myeloid leukemia blasts at diagnosis and at relapse. Leukemia 15:128–133PubMedCrossRef

43.

Yokoyama WM (1998) Natural killer cell receptors. Curr Opin Immunol 10:298–305PubMedCrossRef

44.

Yu YY, George T, Dorfman JR, Roland J, Kumar V, Bennett M (1996) The role of Ly49A and 5E6(Ly49C) molecules in hybrid resistance mediated by murine natural killer cells against normal T cell blasts. Immunity 4:67–76PubMedCrossRef

Titel: Ly49G2 receptor blockade reduces tumor burden in a leukemia model but not in a solid tumor model
verfasst von: Melissa A. Barber
Tong Zhang
Bethany A. Gagne
Jo A. Van Ginderachter
Patrick De Baetselier
Charles L. Sentman
Publikationsdatum: 01.05.2008
Verlag: Springer-Verlag
Erschienen in: Cancer Immunology, Immunotherapy / Ausgabe 5/2008
Print ISSN: 0340-7004
Elektronische ISSN: 1432-0851
DOI: https://doi.org/10.1007/s00262-007-0404-2

Neu im Fachgebiet Onkologie

23.04.2024 | Medikamente in Schwangerschaft und Stillzeit | Nachrichten

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Ly49G2 receptor blockade reduces tumor burden in a leukemia model but not in a solid tumor model

Abstract

Background

Results

Conclusion

Neu im Fachgebiet Onkologie

ICI-Therapie in der Schwangerschaft wird gut toleriert

Krebspatienten impfen: Was? Wen? Und wann nicht?

Müde im Alter? Auch an die Nebenniere denken

Stufenschema weist Prostatakarzinom zuverlässig nach

Update Onkologie

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Background

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 5/2008

Acknowledgement

Histone deacetylase inhibitors induce TAP, LMP, Tapasin genes and MHC class I antigen presentation by melanoma cells

MYCN as a target for cancer immunotherapy

Impact of the CCR5 gene polymorphism on the survival of metastatic melanoma patients receiving immunotherapy

Characterization of HLA class I altered phenotypes in a panel of human melanoma cell lines

Clinical impact of HLA class I expression in rectal cancer

Neu im Fachgebiet Onkologie

ICI-Therapie in der Schwangerschaft wird gut toleriert

Krebspatienten impfen: Was? Wen? Und wann nicht?

Müde im Alter? Auch an die Nebenniere denken

Stufenschema weist Prostatakarzinom zuverlässig nach

Update Onkologie